Hybio Pharmaceutical Co., Ltd.
300199
Κατάταξη σε μετοχές
#4739
Established in 1998 and headquartered in Shenzhen, China, Hybio Pharmaceutical... Established in 1998 and headquartered in Shenzhen, China, Hybio Pharmaceutical Co., Ltd. specializes in the global research, development, manufacturing, and commercialization of therapeutic peptide active pharmaceutical ingredients (APIs) and polypeptide medications. Its diverse product range addresses therapeutic needs such as diabetes (including liraglutide, semaglutide, and exenatide), gastrointestinal and metabolic disorders (with examples like terlipressin, desmopressin, and linaclotide), as well as applications in obstetrics and gynecology (featuring ganirelix, cetrorelix, and atosiban). Additionally, the company supplies custom peptides and provides essential working standards for peptide APIs and their impurities, offering comprehensive support for development initiatives. Beyond products, Hybio extends its expertise through Contract Research Organization (CRO) and an extensive Contract Development and Manufacturing Organization (CDMO) platform. This platform covers peptide API synthesis and purification process optimization, finished dosage form conceptualization, reference standard preparation and rigorous qualification, detailed impurity and product quality analysis, Good Manufacturing Practice (GMP) systems adhering to both EU and FDA benchmarks, and comprehensive regulatory and dossier support for both international and Chinese markets.
Τιμή μετοχής
$3.69
Κεφαλαιοποίηση
$3.11B
Αλλαγή (1 ημέρα)
-7.75%
Αλλαγή (1 έτος)
21.56%
Χώρα
CN
Εμπόριο Hybio Pharmaceutical Co., Ltd. (300199)
Κατηγορία
Healthcare
Ιστορικό μερισματικής απόδοσης για Hybio Pharmaceutical Co., Ltd. (300199)
Η μερισματική απόδοση (TTM) της Hybio Pharmaceutical Co., Ltd. (σύμβολο μετοχής: 300199) στις 2024-12-31 ήταν: 1.00%
Μέση μερισματική απόδοση τα τελευταία 5 χρόνια: 0.87%
Μέση μερισματική απόδοση τα τελευταία 5 χρόνια: 0.87%
Ιστορικό μερισματικής απόδοσης για Hybio Pharmaceutical Co., Ltd. (300199) από 2007 έως 2026
Μερισματική απόδοση στο τέλος κάθε έτους (TTM)
| Έτος | Μερισματική απόδοση | Αλλαγή |
|---|---|---|
| 2026 (TTM) | 0.00% | -100.00% |
| 2025 | 0.58% | -42.00% |
| 2024 | 1.00% | 1.01% |
| 2023 | 0.99% | 33.78% |
| 2022 | 0.74% | -28.85% |
| 2021 | 1.04% | -41.90% |
| 2020 | 1.79% | -20.09% |
| 2019 | 2.24% | -27.97% |
| 2018 | 3.11% | 270.24% |
| 2017 | 0.84% | 110.00% |
| 2016 | 0.40% | 17.65% |
| 2015 | 0.34% | 385.71% |
| 2014 | 0.07% | -68.18% |
| 2013 | 0.22% | -86.67% |
| 2012 | 1.65% | 0.00% |
| 2011 | 0.00% | -100.00% |
| 2010 | 0.07% | -95.10% |
| 2009 | 1.43% | 41.58% |
| 2008 | 1.01% | 0.00% |
| 2007 | 0.00% | 0.00% |
Μερισματικές αποδόσεις (TTM) για παρόμοιες εταιρείες ή ανταγωνιστές
| Εταιρεία | Μερισματική απόδοση | Χώρα |
|---|---|---|
| 1.63% |
DE
|
|
| 1.50% |
DE
|
|
| 3.18% |
JP
|
|
| 0.19% |
CH
|
|
| 0.91% |
IN
|
